Objectives Smoking patterns and cessation rates vary widely across smokers and can be influenced by variation in rates of nicotine metabolism [i.e. cytochrome P450 2A6 (CYP2A6), enzyme activity]. There is high heritability of CYP2A6-mediated nicotine metabolism (60-80%) owing to known and unidentified genetic variation in the CYP2A6 gene. We aimed to identify and characterize additional genetic variants at the CYP2A6 gene locus.
Introduction
Smoking patterns and rates of smoking cessation vary widely among smokers. Variation in nicotine metabolism rate and clearance is primarily mediated by the hepatic enzyme cytochrome P450 2A6 (CYP2A6) [1, 2] . Variation in nicotine metabolism is associated with differences in smoking quantities, dependence, and cessation such that smokers who exhibit a slower rate of nicotine metabolism often smoke less, have lower nicotine dependence scores, and are more likely to quit smoking [3] [4] [5] [6] . In addition, nicotine metabolism rate can be used to predict therapeutic response to smoking cessation pharmacotherapies, including behavioral counseling, nicotine replacement therapy, bupropion, and varenicline [4, 7, 8] . The relationship between the nicotine metabolism rate and smoking quantity stems from smokers' ability to titrate their nicotine intake from cigarettes to maintain consistent nicotine blood levels throughout the day and avoid withdrawal [9] . Nicotine dependence and cessation may be modulated by nicotine metabolism rate such that normal, compared with slow, nicotine metabolizers have greater fluctuation of blood nicotine concentrations, which may result in enhanced reward, altered strength of functional conductivity between rewarding brain regions, and increased conditioned responses to smoking cues [6, 10, 11] .
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Heritability estimates suggest that 60-80% of the variation in nicotine metabolism is attributable to genetic influences, with known CYP2A6 genetic variants accounting for ∼ 20-30% of the variation [12, 13] . Only a small contribution arises from environmental or nongenetic factors; dietary or pharmacological agents, sex and estrogen consumption, age, BMI, alcohol consumption, and smoking account for ∼ 8% of the variation [14] [15] [16] [17] [18] . CYP2A6 gene locus polymorphisms are associated with differences in nicotine metabolism in vitro and in vivo [17, 19, 20] , and correspondingly with smoking behaviors [3, 21] . In a recent genome-wide association study (GWAS) of CYP2A6 activity, all three independent genome-wide significant signals were within or near the CYP2A6 locus [12] . The CYP2A6 gene is highly polymorphic, with more than 40 genetic variants characterized to date (http://www.cypalleles.ki.se/cyp2a6.htm). Thus, it is likely that genetic variation in CYP2A6 remains unaccounted for, contributing to the high heritability of the nicotine metabolism phenotype.
Part of the difficulty in fully characterizing CYP2A6 genetic variation is high sequence homology of CYP2A6, CYP2A7, and CYP2A13 [22] . Consequently, CYP2A6 genotyping typically requires a two-step approach that first ensures specificity to CYP2A6 followed by characterization of the specific variant of interest [23] . However, to perform large-scale evaluations of the CYP2A6 locus for identification of novel genetic variation, there is a need for sequencing approaches that both account for high homology with other genes and are highthroughput. In this study, we describe a new method for sequencing this gene, examine novel (i.e. uncharacterized) and existing CYP2A6 genetic variation, and characterize seven novel high-frequency single nucleotide polymorphisms (SNPs) with respect to CYP2A6 enzyme activity in a human liver bank in-vitro assessment and using an in-vivo phenotype measure.
Methods

Overview
Using CYP2A6-specific next-generation sequencing, we identified and characterized novel CYP2A6 genetic variants. Sequencing was performed at the CYP2A6 locus and surrounding region (hg38 40843538-40852095) for White (N = 42) and African-American (N = 170) patients. The sequencing sample set consisted of DNA from patients from a human liver bank (N = 43) [17] , a pharmacokinetic study (N = 57) [24] , and two smoking cessation clinical trials (KIS2 N = 26, and KIS3 N = 86) [25, 26] . We prioritized potentially functional SNPs and characterized the association of each SNP with CYP2A6 phenotypes in a human liver bank previously characterized for CYP2A6 (CYP2A6 sequenced, mRNA, protein, and enzyme activity quantified). Finally, we assessed the linkage and haplotype structure of the SNPs, and the effect of resulting diplotypes on in-vitro and in-vivo CYP2A6 activity, in the liver bank and in a population of treatment-seeking smokers from a smoking cessation clinical trial [Pharmacogenetics of Nicotine and Addiction Treatment clinical trial (PNAT), NCT01314001] [7] .
CYP2A6-specific sequencing
DNA from 212 White and African-American patients was sequenced at the CYP2A6 locus, using CYP2A6-specific sequencing, to thoroughly interrogate SNPs at this locus for further testing. Library preparation, sequencecapture, sequencing on Illumina (San Diego, California, USA) MiSeq, and sequence analysis were conducted as outlined in Supplementary Method 1 (Supplemental digital content 1, http://links.lww.com/FPC/B285).
Novel CYP2A6 SNPs identified in the region (hg38) 40843538-40852095 (3′-UTR to 2 kb 5′ of CYP2A6) were analyzed for potential effect on CYP2A6 using the following bioinformatics tools: ensemble genome browser [27] , GTEx Portal [28] , RegulomeDB [29] , RegRNA 2.0 [30] , HaploReg v4.1 [31] , RESCUE-ESE [32] , and FAS-ESS [33] . A final subset of novel SNPs predicted to affect CYP2A6 was further investigated in a human liver bank (described below).
Liver bank CYP2A6 PGRN-sequencing and genotyping
The CYP2A6 locus was previously sequenced in the full human liver bank using PGRN-Seq [34] , an earlier sequencing platform before further optimization for CYP2A6 (Supplementary Method 2, Supplemental digital content 1, http://links.lww.com/FPC/B285). These CYP2A6 sequence data were one mechanism used to genotype SNP calls in the liver bank for novel SNPs identified by CYP2A6-specific sequencing (described above), and the other method consisted of traditional genotyping approaches. SNP genotype calls for the (N = 43) liver bank samples included in the original exploratory CYP2A6-specific sequencing were made according to PGRN-Seq or direct genotyping, to remain consistent with genotype calls for the rest of the human liver bank (see Table 1 for summaries of samples used). Most SNP genotype calls in the liver bank were readily available from PGRN-seq data; calls were then verified using traditional genotyping approaches (described below).
Genotyping for established CYP2A6 genetic variants common among White populations (CYP2A6*2, *4, *9, *12) was performed using two-step allele-specific PCR genotyping or TaqMan SNP genotyping (Applied Biosystems/ ThermoFisher Scientific, Waltham, Massachusetts, USA), as reported previously [17, 23] . Concordance between the genotype and PGRN-Seq calls for established SNPs CYP2A6*2 (rs1801272) and *9 (rs28399433) was 99 and 98%, respectively; CYP2A6*4 and *12 are copy number and hybrid variants not identified by this sequencing method. Next, we verified liver bank PGRN-Seq SNP calls with traditional genotyping approaches that consisted of direct genotyping (TaqMan or SYBR Green SNP genotyping assays) for the seven novel SNPs that exhibited significant associations with CYP2A6 phenotypes (Supplementary Table 1 , Supplemental digital content 1, http://links.lww.com/FPC/B285). Concordance of genotyping and PGRN-Seq SNP calls was assessed (5/7 SNPs were detected by PGRN-Seq) and was high for all SNPs, ranging from 84 to 97%. For subsequent genotype-phenotype analyses, calls for the seven novel SNPs were made using PGRN-Seq data (i.e. data from an earlier sequencing platform) unless concordance was less than 90% (N = 3) or was not available (N = 2), in which case TaqMan or SYBR green genotype data were used.
Quantifying in-vitro CYP2A6 phenotypes
Genotype-phenotype associations for novel SNPs were assessed in White patients in the full liver bank data set (N = 332). Measurements of CYP2A6 mRNA, protein, and enzyme activity in the liver bank have been described previously [17] . Briefly, CYP2A6 mRNA expression was quantified using RNA sequencing (values expressed as fragments/kb/million reads, FPKM). CYP2A6 protein was quantified using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) proteomics method. In-vitro CYP2A6 enzyme activity was determined by quantifying the rate of nicotine metabolism to cotinine in liver microsomes.
Clinical trial CYP2A6 genome-wide association study and genotyping A GWAS of nicotine metabolite ratio (NMR) in the PNAT trial was used to ascertain SNP genotype calls for the seven novel SNPs (GWAS methodology described in detail by Chenoweth et al. 2017 [35] ). In summary, genome-wide SNP genotyping was performed using the Illumina HumanOmniExpressExome-8 v1.2 array (Illumina). Genotypes were imputed using IMPUTE2 software [36] , and all variants had a quality score more than 0.85 and minor allele frequency (MAF) more than 1%, and thus were included in analyses. In addition, samples were genotyped for the same established CYP2A6 genetic variants (CYP2A6*2, *4, *9, *12) [23] . GWAS and genotyping SNP calls were 99.8 and 99.2% concordant for *2 and *9, respectively, supporting the concordance of GWAS SNP calls for the novel variants.
Assessing linkage and haplotype structure of novel single nucleotide polymorphisms Using Haploview [37] , we estimated the linkage disequilibrium (LD) and haplotype structure of the seven novel SNPs separately in the liver bank and PNAT trial. Analyses were restricted to White patients not possessing any previously established CYP2A6 genetic variants (i.e. CYP2A6*2, *4, *9, *12; liver bank N = 252, PNAT N = 536). For SNP pairs in high LD (r 2 ≥ 0.80) in PNAT (the larger study population), one SNP from each pair was selected to include in a simplified haplotype, resulting in a final haplotype composed of five SNPs. Using the PHASE program [38, 39] , five-SNP haplotypes were phased (8360 bp genomic distance) to predict five-SNP diplotypes in both studies.
Clinical trial CYP2A6 phenotyping
In-vivo CYP2A6 activity was measured in blood at baseline for treatment-seeking smokers in the PNAT trial by quantifying the ratio of nicotine's metabolites, trans-3′-hydroxycotinine/cotinine, a measure referred to as the NMR, using LC-MS/MS [7] , as described previously [40, 41] . Limits of quantification for each metabolite were 1 ng/ml of blood.
Statistical analyses
We assessed the association of each of the seven novel SNPs with CYP2A6 mRNA, protein, and enzyme activity in the liver bank using Kruskal-Wallis and Dunn's multiple comparisons tests or the MannWhitney test. The same tests were used to evaluate the association of the seven and five-SNP diplotypes with CYP2A6 activity in the liver bank and PNAT trial. We ran nested linear regression models for CYP2A6 activity to calculate the additional proportion of variation that is accounted for by the seven SNPs, or the simplified five-SNP haplotype, relative to what was accounted for by the established CYP2A6 genetic variants alone. Genotypes were the only predictors included in these models. Analyses were performed using GraphPad Prism (v.6.0; GraphPad Software Inc., LaJolla, California, USA) and SPSS (v.23; IBM, Armonk, New York, USA), and statistical tests were considered significant for P value of less than 0.05. were sufficiently common to be used in analyses of relationships with in-vitro CYP2A6 activity in the liver bank (described below); the remaining eight novel SNPs were rare (MAF <1% in 1000 genomes), and we were not powered to investigate these in the liver bank. Of the 13 common SNPs, seven were significantly associated with CYP2A6 activity in the liver bank (described below), and were therefore prioritized for further investigation. Patients possessing any of the SNPs identified through sequencing (i.e. rare or nonsignificant SNPs) were included in all of the following analyses.
Of the seven prioritized SNPs, four are located 5′ of CYP2A6 [rs57837628, rs7260629, rs7259706, rs150298687 (also denoted rs4803381)], two are located in introns (rs56113850, rs28399453), and one in the 3′-UTR (rs8192733) ( Table 2 ). The seven SNPs are common in White populations in 1000 genomes (6 − 70%), the human liver bank (7 − 72%), and the PNAT trial (7 − 69%). The total number of samples from the liver bank and PNAT trial that were included in subsequent analyses is provided in Table 1 .
Association of seven novel SNPs with CYP2A6 phenotypes
All seven novel SNPs were significantly associated with higher in-vitro CYP2A6 activity, each exhibiting a genedose effect (P values provided in Fig. 1 and Table 3 ). Six of the seven SNPs were significantly associated with higher CYP2A6 protein levels (P values 0.49 to <0.0001),
with the exception of rs28399453 (P = 0.11, same direction of effect) ( Table 3 ). None of the seven SNPs significantly altered CYP2A6 mRNA expression (all P > 0.11); however, they all indicated a similar direction of effect. Similar relationships between the novel SNPs and CYP2A6 phenotypes were observed when restricting analyses to CYP2A6*1/*1 genotype liver donors (i.e. excluding donors with established CYP2A6 genetic variants, N = 63 White liver donors).
To determine if the novel SNPs collectively accounted for any additional variation in CYP2A6 activity in the liver bank, we performed nested linear regression modeling. The previously established CYP2A6 genetic variants (*2, *4, *9, *12) alone accounted for 2.1% of the variation in CYP2A6 activity (model 1: r 2 = 0.021, P = 0.009). When the seven novel SNPs were added to the model, they accounted for an additional 4.5% of CYP2A6 activity variation (model 2: r 2 = 0.066, P = 0.005), relative to the established variants (model 1 vs. model 2: r 2 change = 0.045, P = 0.03).
Linkage and haplotype structure for seven novel SNPs
Owing to the high-frequency of the seven novel SNPs and their similar effect on CYP2A6, we assessed linkage and haplotype structure. Haploview was used to predict r 2 , D′, and haplotype blocks in liver donors and PNAT treatmentseeking smokers. The seven novel SNPs were not in LD with established CYP2A6 genetic variants (*2, *4, *9, *12) in either the liver bank or PNAT trial (r 2 = 0.00 − 0.07; Supplementary Fig. 1 , Supplemental digital content 1, http:// links.lww.com/FPC/B285 ). Further analyses were restricted to patients without established CYP2A6 genetic variants. In the liver bank, of the seven novel SNPs, two SNP pairs were in high LD (r 2 > 0.8, D′ > 0.9): (a) rs57837628 and rs8192733, and (b) rs56113850 and rs150298687, with the rs7260629 and rs7259706 pair falling just below threshold (r 2 = 0.79) (Fig. 2a) . In the PNAT trial, two SNP pairs were in high LD: (a) rs57837628 and rs8192733, (b) rs7260629 and rs7259706 (Fig. 2b) . SNP rs28399453 was not in LD with any of the other six SNPs in either study population (r 2 = 0.03 − 0.07). Owing to the high linkage among the novel SNPs, we chose to exclude one SNP from each of the high LD SNP pairs that were present in PNAT, the larger study population, (i.e. rs57837628 and rs8192733; rs7260629 and rs7259706) and investigate CYP2A6 phenotype associations for a simplified set of five SNPs: rs28399453, rs56113850, rs150298687, rs7260629, and rs57837628. We then quantified the proportion of variation in CYP2A6 activity in the liver bank additionally accounted for by the five SNPs, relative to the established CYP2A6 CYP2A6 diplotypes and nicotine metabolism Tanner et al. 11
variants alone, using regression modeling. The five novel SNPs accounted for an additional 3.9% of the variation in CYP2A6 activity (model 2: r 2 = 0.060, P = 0.003) compared with the established variants (model 1: r 2 = 0.021, P = 0.009; model 1 vs. model 2: r 2 change = 0.039, P = 0.02).
Five-SNPs diplotypes in the liver bank and PNAT trial
The PHASE software was used to predict seven and five-SNP diplotypes. Of note, when phasing the established CYP2A6 genetic variants and the seven novel SNPs, several compound heterozygotes were identified consisting of both established and novel variants; however, we were not powered to assess the functional significance of these compound heterozygotes owing to low genotype frequencies. As a result, and owing to the lack of LD for established CYP2A6 genetic variants with the novel SNPs (r 2 = 0.00 − 0.07; Supplementary Fig. 1 , Supplemental digital content 1, http://links.lww.com/FPC/B285), patients possessing established CYP2A6 genetic variants (*2, *4, *9, *12) were therefore excluded from analyses. Summaries of seven-SNP diplotypes in the liver bank and PNAT have been provided in Supplementary Tables 4 and 5 (Supplemental digital content 1, http:// links.lww.com/FPC/B285, respectively). With respect to the simplified group of five novel SNPs, there were 25 distinct diplotypes total in the liver bank (Table 4 ) and 40 diplotypes in PNAT (Table 5 ). The full reference diplotype (GTTTA/GTTTA; reference allele designated according to dbSNP, and corresponds to the CYP2A6*1 allele) was present in 6.6 and 6.4% of samples from the subset of the liver bank and PNAT, respectively. Of note, not all diplotypes observed in the liver bank appeared in PNAT; diplotypes #12, #16-21, and #23-24 (Table 4) were not found among PNAT patients (Table 5) . Furthermore, 24 additional diplotypes were present in PNAT, which were not identified in the liver bank (diplotypes #16-39, Table 5 ).
Association of five-SNPs diplotypes and CYP2A6 activity in vitro and in vivo
We compared the rate of in-vitro CYP2A6 activity (rate of cotinine formation from nicotine) of the top 5 most frequent diplotypes in the liver bank (diplotypes #1-5, Table 4 ) to that of the reference diplotype (Table 4) , which does not possess the variant form of any of the five SNPs (Fig. 3a) . Of note, several liver bank donors were missing CYP2A6 activity data while still having genotype/sequence data, and therefore were excluded from phenotype analyses in Fig. 3 , but were included in the summary of diplotypes in Table 4 . Each of the five most frequent diplotypes had higher mean CYP2A6 activity compared with the reference diplotype (P = 0.23). Additionally, when collapsed together into one group, the five most frequent diplotypes collectively had nonsignificantly higher mean CYP2A6 activity compared with the reference diplotype (P = 0.28), which was also observed for the remaining diplotypes combined (diplotypes #6-24, Table 4 ; P = 0.28), and when all variant diplotypes were grouped together (diplotypes #1-24; P = 0.26).
To increase our power for assessing associations between diplotypes and CYP2A6 activity (N = 252 patients analyzed in the liver bank), we extended these analyses to the PNAT sample (N = 536). In PNAT, we compared the mean NMR between the reference diplotype and the top five most frequent diplotypes that were found in the liver bank (diplotypes #1-5, Table 5 and Fig. 3b ). Only diplotypes that were found in the liver bank were included in diplotype-phenotype analyses in PNAT. Compared with the full reference diplotype, diplotypes #1-4 (Table 5 ) each had significantly higher mean NMR (P values 0.008 to <0.0001). Diplotype #5, which only possesses the variant form of one of the five SNPs, exhibited nonsignificantly higher mean NMR (P > 0.99), relative to the reference diplotype. The combined diplotype groups #1-5, #6-24, and #1-24 had significantly higher mean NMR compared with the reference diplotype (all P < 0.0001). Analyses of the top five most frequent seven-SNP diplotypes were also conducted in the liver bank and PNAT trial; these illustrated very similar patterns for association of frequent diplotypes with CYP2A6 in-vitro and in-vivo activity ( Supplementary Fig. 2 , Supplemental digital content 1, http://links.lww.com/FPC/B285) as was observed for the frequent five-SNP diplotypes.
Discussion
We have identified seven novel SNPs, and a resulting simplified five-SNP diplotype, at the CYP2A6 locus, which significantly affect CYP2A6 activity assessed in both a human liver bank in vitro and using the NMR in vivo. All seven novel SNPs characterized here were noncoding variants, present in regulatory and intronic regions of the CYP2A6 gene, with MAFs more than 1% in European ancestry populations (liver bank: 7 − 72%, PNAT: 7 − 69%). Noncoding variants are largely understudied, despite important roles in regulating transcription, chromatin state, splicing, and epigenetic modifications; this work further highlights the utility of full gene or genome sequencing in characterizing complex traits and diseases, such as smoking.
For the novel SNPs characterized here that were in high LD, allowing for incorporation of only one of the two SNPs into the simplified five-SNP diplotype, LD was similarly moderate to high in a GWAS of the NMR in a Finnish population (rs57837628 and rs8192733 r 2 = 0.73, rs7260629 and rs7259706 r 2 = 0.98) [12] . Likewise, associations of CYP2A6 diplotypes with in-vitro and in-vivo rate of nicotine metabolism were consistent for the seven CYP2A6 diplotypes and nicotine metabolism Tanner et al. 13
and five-SNP diplotypes (see Fig. 3 and Supplementary  Fig. 2 , Supplemental digital content 1, http://links.lww. com/FPC/B285), and there was little change in the amount of variation in CYP2A6 enzyme activity accounted for by all seven SNPs compared with only five SNPs (6.6 vs. 6.0%). This supports the use and assessment of the five-SNP diplotype, as opposed to all seven SNPs, in CYP2A6 phenotype association studies and in future genotype-prediction algorithms. As we were able to capture significantly more of the variation in CYP2A6 activity with the five-SNP diplotype (additional 3.9% compared to established variants alone), in the future, as we capture more and more of the heritable variation in CYP2A6, we may be able to use CYP2A6 genotype to tailor smoking cessation. As feasibility of genomics-based treatment optimization increases, implementation of preemptive genotyping will require further assessment of both coding and noncoding genetic variation, and incorporation of genotypes into functionally significant diplotypes, as demonstrated here.
Our in-vitro and in-vivo functional characterization of novel SNPs expands on previous GWASs that have identified significant hits at CYP2A6. Consistent with our prioritization, six of the seven SNPs in our investigation reached genomewide significance (rs28399453 did not, P = 6.42E − 06) in the Finnish GWAS of the NMR, with rs56113850 being the top hit (most highly significant, P = 5.77E − 86) [12] . rs56113850 was also the top hit for association with NMR in a multiethnic cohort (MEC) study in which it was globally significantly associated with higher CYP2A6 activity (P = 1.19E − 50), and it was the second most significant SNP associated with lung cancer risk in the TRICL consortium GWAS (P = 5.78E − 11) [42] . Similarly, rs56113850 was the SNP IDs that make up the CYP2A6 diplotype (in order): rs28399453 (G>A), rs56113850 (T>C), rs150298687 (T>C), rs7260629 (T>G), rs57837628 (A>G) Diplotypes Reference: Comparison of cytochrome P450 2A6 (CYP2A6) enzyme activity of the full reference diplotype group and top five most frequent five-SNP CYP2A6 diplotypes. Data were restricted to White patients and to those without established CYP2A6 genetic variants. Enzyme activity for the total group (i.e. before splitting into diplotype groups) has been provided as a reference in each figure (far left). The diplotype group numbers refer to Tables 4 and 5. (a) Data from the human liver bank. In-vitro CYP2A6 activity was measured as the rate of cotinine formation (nmol/min/mg) from nicotine [17] . For reference, the mean ( SD) cotinine formation for the pooled established variant group from the liver bank is 0.07 ( 0.09), as described previously [17] . (b) Data from the PNAT trial. In-vivo CYP2A6 activity was measured using the ratio of nicotine's metabolites (3HC/COT, nicotine metabolite ratio, NMR) [40, 41] . For reference, the mean ( SD) NMR for the pooled established variant group from PNAT is 0.30 ( 0.17). The 25 diplotypes found in the liver bank (Table 4) were compared with the same diplotypes in PNAT, to maintain consistency of the comparison; it should be noted, however, that some low-frequency diplotypes among the 25 in the liver bank were not found in PNAT (diplotypes #12, #16-21, and #23-24 from Table 4) , and likewise several low-frequency diplotypes in PNAT were not found in the liver bank (diplotypes #16-39; Table 5 ). Therefore, these diplotype groups were excluded from the PNAT phenotype analyses (b). P values are based on Kruskal-Wallis and Dunn's multiple comparison tests, or Mann-Whitney tests. Among PNAT treatment-seeking smokers, the relationship between the reference diplotype and top 5 diplotype groups remained similar and significant when accounting for the nongenetic factors 'age' and 'sex' (P < 0.001), using regression modeling. PNAT, Pharmacogenetics of Nicotine and Addiction Treatment.
top ranked European American SNP in a separate GWAS of NMR (P = 3.81E − 10) [43] . SNPs rs57837628 and rs8192733 were also globally significant in the MEC (P = 6.84E − 37 and 2.78E − 08, respectively), and were associated with increased lung cancer risk in the TRICL consortium GWAS (P = 4.01E − 10 and 2.10E − 9, respectively) [42] . The remaining SNPs, rs7260629, rs7259706, rs150298687, and rs28399453, were not significant in the MEC or TRICL consortium GWASs [42] . Lack of genomewide significance of rs28399453 in the Finnish GWAS of NMR may result from lower allele frequency (liver bank: 7%, PNAT: 7%, 1000 genomes: 6% for European ancestry) relative to the other six novel SNPs (liver bank: 47 − 72%, PNAT: 47 − 69%, 1000 genomes: 48 − 70% for European ancestry), and in the MEC study owing to even lower allele frequencies across populations of other ethnic origins (0, 0, and 2% among African, Asian, and Latin American ancestry populations, respectively, from 1000 genomes).
We also identified novel exon variation in CYP2A6 through sequencing (N =46 exon SNPs); only six missense and one nonsense SNPs were found, all of which were rare (MAF < 1% in 1000 genomes). This finding is consistent with most CYP genes where 93 and 83% of coding region SNPs are rare (MAF < 1%) or very rare (MAF < 0.1%), respectively [44] . Owing to the infrequency of nonsynonymous coding region SNPs in the current study, we were not powered to characterize functional effect in the liver bank (Supplementary Table 1 , Supplemental digital content 1, http://links.lww. com/FPC/B285). Functional investigation of these SNPs may require the use of an in-vitro CYP2A6 cDNA expression system [45] , in combination with the BioBin software [46] , which improves power to detect phenotype associations by combining rare variants.
In addition to a lack of power for investigating rare coding variation, a study limitation is the assessment of White populations only. Frequency of CYP2A6 genetic variation differs substantially across ethnic groups [47] , suggesting that our results may not extend to other ethnic populations. Additionally, owing to haplotype and LD structure heterogeneity across different populations [48] , the utility of the simplified five-SNP diplotype for predicting CYP2A6 activity and nicotine metabolism should be reassessed independently among other ethnic groups.
Furthermore, our study was limited by the lack of assessment of structural and copy number variants at the CYP2A6 locus. Copy number variants, such as the established CYP2A6*4 deletion allele, though relatively rare, exhibit a significant effect on CYP2A6 activity; PNAT treatmentseeking smokers with the CYP2A6*1/*4 genotype have a 45% lower mean NMR relative to those without the *4 allele (mean NMR: CYP2A6*1/*4, 0.23; CYP2A6*1/*1, 0.42; P < 0.0001).
Conclusion
Seven novel high-frequency CYP2A6 SNPs were identified as important contributors to CYP2A6 phenotypes, accounting for approximately two times more variation in CYP2A6 activity, compared with established CYP2A6 variants alone. Owing to high LD between two pairs of the seven novel SNPs, we established a functional five-SNP haplotype, which, when phased to derive diplotypes, was associated with CYP2A6 enzyme activity invitro and in-vivo in a human liver bank and PNAT clinical trial, respectively. Considering the association of CYP2A6 enzyme activity with smoking behavior and cessation outcomes, it will be important to determine the utility of incorporating the five-SNP diplotype into CYP2A6 genotype models for predicting cessation success and response to pharmacotherapies.
